Announcements Trials
Browse Landscape

Phase

Phase 2 3Phase 2/3 2Phase 1/2 2Phase 1 2Phase 3 1

Status

Completed 51Terminated 21Active not recruiting 12Withdrawn 8Recruiting 5Not yet recruiting 2Unknown 1

Sponsor Class

OTHER 1NIH 1

Study Type

Interventional 2

Sponsor

Cancer Type

Plasma cell 1Lymphoid 1Breast 1

Conditions

Triple Negative Breast Neoplasms 1Multiple Myeloma 1Ann Arbor Stage II Mantle Cell Lymphoma 1

Interventions

Cyclophosphamide 22fludarabine 17Specimen Handling 14Magnetic Resonance Spectroscopy 10Nivolumab 9pembrolizumab 8Cisplatin 7Radiotherapy 6fludarabine phosphate 5Injections 5Doxorubicin 5Biopsy 5tislelizumab 4daratumumab 4Rituximab 4Paclitaxel 4Ipilimumab 4Interleukin-2 4Immune Checkpoint Inhibitors 4Gemcitabine 4Fluorouracil 4Drug Therapy 4Dexamethasone 4Carboplatin 4venetoclax 3toripalimab 3ruxolitinib 3X-Rays 3Vincristine 3Radiosurgery 3

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Phase 1 × Not yet recruiting × Calcium Dobesilate × Clear all
NCT07444710 2026-05-13

Testing the Addition of an Anti-Cancer Drug, Glofitamab, to the Usual Chemotherapy Treatment (Alternating R-CHOP/R-DHAP) for Previously Untreated Mantle Cell Lymphoma

National Cancer Institute (NCI)

Phase 1 Not yet recruiting
16 enrolled
Lymphoid

Ann Arbor Stage II Mantle Cell Lymphoma

NCT07341867 2026-01-14

Systemic Anti-Cancer Therapy Dose Modifications for Individuals With Duffy Null Phenotype

Dana-Farber Cancer Institute

Phase 1 Not yet recruiting
90 enrolled
BreastPlasma cell

Multiple Myeloma, Triple Negative Breast Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡